Lilly Comfortable With Zyprexa's Second Place Detailing
This article was originally published in The Pink Sheet Daily
Executive Summary
Company notes it is second behind Johnson & Johnson's Risperdal. Reports that Zyprexa detailing has fallen off by 30% "could be overstated," Lilly says. Lilly is pleased with the current level of detailing for both Zyprexa and Cymbalta.